Journal
PHARMACEUTICAL RESEARCH
Volume 27, Issue 7, Pages 1426-1436Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-010-0138-2
Keywords
amphipathic helix; cationic peptides; gene therapy; histidine; RNA interference
Funding
- Vaincre la Mucoviscidose (VLM)
- Association Francaise contre les Myopathies (AFM)
- ANR Transpep [PCV07_186700]
- Wellcome Trust
Ask authors/readers for more resources
Short linear peptides have a high potential for delivering various drugs with therapeutic potential, including nucleic acids. Recently, we have shown that the cationic amphipathic histidine-rich peptide LAH4 (KKALLALALHHLAHLALHLALALKKA) possesses high plasmid DNA delivery capacities. Since such peptides are thought to efficiently disrupt endosomal membranes, we have tested their ability to deliver small interfering RNA (siRNA) into mammalian cells. Using a human cell line stably transfected with a luciferase-encoding expression vector, we have evaluated the ability of LAH4 and five derivatives thereof to deliver siRNAs and silence gene expression. The six peptides are all efficient siRNA delivery vehicles whose efficiency in mediating gene silencing in 911-Luc cells was greater than that of commercially available compounds including Lipofectamine, DOTAP and polyethylenimine. In addition, by using the proton pump inhibitor bafilomycin A1, we show that efficient siRNA delivery to the cytosol requires acidification of the endosomes. The LAH4 histidine-rich cationic amphipathic peptides represent an interesting and promising family of compounds for siRNA delivery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available